Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review
Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/2/174 |
| _version_ | 1797763799326916608 |
|---|---|
| author | Denise Fabian Maria del Pilar Guillermo Prieto Eibl Iyad Alnahhas Nikhil Sebastian Pierre Giglio Vinay Puduvalli Javier Gonzalez Joshua D. Palmer |
| author_facet | Denise Fabian Maria del Pilar Guillermo Prieto Eibl Iyad Alnahhas Nikhil Sebastian Pierre Giglio Vinay Puduvalli Javier Gonzalez Joshua D. Palmer |
| author_sort | Denise Fabian |
| collection | DOAJ |
| description | Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations. |
| first_indexed | 2024-03-12T19:46:30Z |
| format | Article |
| id | doaj.art-ba459baf9d2b40eb829030ab3293a436 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:46:30Z |
| publishDate | 2019-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ba459baf9d2b40eb829030ab3293a4362023-08-02T03:30:56ZengMDPI AGCancers2072-66942019-02-0111217410.3390/cancers11020174cancers11020174Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A ReviewDenise Fabian0Maria del Pilar Guillermo Prieto Eibl1Iyad Alnahhas2Nikhil Sebastian3Pierre Giglio4Vinay Puduvalli5Javier Gonzalez6Joshua D. Palmer7Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USADepartment of Neuro-Oncology, The Ohio State University, Columbus, OH 43210, USADepartment of Neuro-Oncology, The Ohio State University, Columbus, OH 43210, USADepartment of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USADepartment of Neuro-Oncology, The Ohio State University, Columbus, OH 43210, USADepartment of Neuro-Oncology, The Ohio State University, Columbus, OH 43210, USADepartment of Neuro-Oncology, The Ohio State University, Columbus, OH 43210, USADepartment of Neuro-Oncology, The Ohio State University, Columbus, OH 43210, USAGlioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.https://www.mdpi.com/2072-6694/11/2/174glioblastomaGBMtumor treating fieldsTTF |
| spellingShingle | Denise Fabian Maria del Pilar Guillermo Prieto Eibl Iyad Alnahhas Nikhil Sebastian Pierre Giglio Vinay Puduvalli Javier Gonzalez Joshua D. Palmer Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review Cancers glioblastoma GBM tumor treating fields TTF |
| title | Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review |
| title_full | Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review |
| title_fullStr | Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review |
| title_full_unstemmed | Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review |
| title_short | Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review |
| title_sort | treatment of glioblastoma gbm with the addition of tumor treating fields ttf a review |
| topic | glioblastoma GBM tumor treating fields TTF |
| url | https://www.mdpi.com/2072-6694/11/2/174 |
| work_keys_str_mv | AT denisefabian treatmentofglioblastomagbmwiththeadditionoftumortreatingfieldsttfareview AT mariadelpilarguillermoprietoeibl treatmentofglioblastomagbmwiththeadditionoftumortreatingfieldsttfareview AT iyadalnahhas treatmentofglioblastomagbmwiththeadditionoftumortreatingfieldsttfareview AT nikhilsebastian treatmentofglioblastomagbmwiththeadditionoftumortreatingfieldsttfareview AT pierregiglio treatmentofglioblastomagbmwiththeadditionoftumortreatingfieldsttfareview AT vinaypuduvalli treatmentofglioblastomagbmwiththeadditionoftumortreatingfieldsttfareview AT javiergonzalez treatmentofglioblastomagbmwiththeadditionoftumortreatingfieldsttfareview AT joshuadpalmer treatmentofglioblastomagbmwiththeadditionoftumortreatingfieldsttfareview |